Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Ceftiofur
Introduction
Overview
Overview
Ceftiofur is an antibiotic of the cephalosporin type (third generation), licensed for use in veterinary medicine. It was first described in 1987.[1] It is marketed by pharmaceutical company Pfizer as Excede.[2]
It is resistant to the antibiotic resistance enzyme beta-lactamase, and has activity against Gram-positive and Gram-negative bacteria. E. coli strains resistant to ceftiofur have been reported.[3]
References
References
- ↑ Yancey RJ, Kinney ML, Roberts BJ, Goodenough KR, Hamel JC, Ford CW (1987). “Ceftiofur sodium, a broad-spectrum cephalosporin: evaluation in vitro and in vivo in mice”. Am. J. Vet. Res. 48 (7): 1050–3. PMID 3631686.
- ↑ “Pfizer Animal ealth Dairy Information on Products and Solutions”. Retrieved 2007-11-20.
- ↑ Donaldson SC, Straley BA, Hegde NV, Sawant AA, DebRoy C, Jayarao BM (2006). “Molecular epidemiology of ceftiofur-resistant Escherichia coli isolates from dairy calves”. Appl. Environ. Microbiol. 72 (6): 3940–8. doi:10.1128/AEM.02770-05. PMID 16751500.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]